The Therapeutic Goods Administration (TGA) hosted the 14th meeting of the Women’s Health Products Working Group (WHPWG) on 15 October 2026.
The WHPWG is comprised of representatives from consumer groups, medical peak bodies, clinicians, industry, academia, and senior officials from the Department of Health, Disability and Ageing (DHDA).
Key topics discussed by the Working Group included:
- The TGA’s participation in collaborative forums addressing national and international women’s health priorities, including key highlights from the European Medicines Agency’s multi-stakeholder workshop on women’s health, which explored opportunities to strengthen the evidence base and support more inclusive and representative clinical research for women.
- Presentation from a leading medical oncologist and breast cancer researcher on the opportunity to transform breast cancer prevention in Australia through personalised risk assessment, targeted preventive therapies and equitable access to specialist prevention services. The session explored how tools such as iPrevent can identify women at increased risk of breast cancer and support earlier intervention, complementing Australia's screening programs with evidence-based prevention strategies. It will also highlight a nationally scalable model of care aligned with the Australian Cancer Plan's focus on personalised prevention and equitable outcomes.
- Presentation from the Australian Digital Health Agency on the future of virtual care and the growing role of telehealth in women's healthcare. The discussion explored opportunities to improve access, convenience and continuity of care, alongside challenges relating to clinical appropriateness, privacy, safety and information sharing. The Agency outlined its work to strengthen governance frameworks and develop of new safety and quality standards for virtual care with the Australian Commission on Safety and Quality in HealthCare to support safe, high-quality and patient-centred telehealth services as demand continues to grow.
- Presentation from the Pharmaceutical Society of Australia on its ongoing work to improve medicine safety for culturally and linguistically diverse (CALD) communities. The presentation explored the impact of misinformation, access to interpreters, culturally responsive care, and the importance of clear and accessible medicines information. Members discussed the need to address language, cultural and health literacy barriers to support safe and informed medicine use, and noted opportunities for further work to improve access to trusted health information and healthcare services for women from diverse backgrounds.
The next WHPWG meeting is scheduled for March 2027, with the date to be confirmed.
Outcome of